Τόμος 17 (2003) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 17 (2003) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Department of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

 Accepted for publication: 20 August 2003

pharmakonpress[at]pharmakonpress[.]gr

2.    Wu Q., Moyana T., Xiang J.: Cancer Gene Therapy by Adenovirus – Mediated Gene Transfer. Curr. Gene Then 1: 101-122 (2001)

3.    Blaese R.M., et al.: Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. Hum. Gene Ther. 1: 327-362 (1990)

4.    Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., et al.: T lymphocyte-directed gene therapy for ADA – SCID: initial trial results after 4 years. Science 270: 475-480 (1995)

5.    Romano G., Pacilio C., Giordano A.: Gene transfer technology in therapy: current applications and future goals. Stem Cells 17: 191-202 (1999)

6.    Dyer M.R., Herrling P.L.: Progress and potential for gene-based medicine. Mol. Ther. 1: 213-224 (2000)

7.    Nadeau I., Kamen A.: Production of Adenovirus Vector for Gene Therapy. Biotechnology Adv. 20: 475-489 (2003)

8.    Ogris M., Wagner E.: Targeting tumors with non-viral gene delivery systems. Drug Discovery Today 7: 479-485 (2002)

9.    Dash P.R., et al.: Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6: 643-650 (1999)

10.  Brown M.D., et al.: Gene delivery with synthetic (non-viral) carriers. Int. J. Pharm. 229: 1-21 (2001)

11.  Kircheis R., et al.: Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med. T: 111— 120 (1999)

12.  Ogris M., et al.: PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6: 595-605 (1999)

13.  Kichler A., et al.: Polyethilenimines: a family of potent polymers for nucleic acid delivery. In: Huang LE. et al.: Nonviral Vectors for Gene Delivery, Academic Press, pp. 191-206, 1999

14.  Wagner E., et al.: Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug. Deliv. Rev. 14: 113-136 (1994)

15.  Kircheis R., et al.: Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4: 409-418 (1997)

16.  Kircheis R., et al.: Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8: 28-40 (2001)

17.  Kourie J.I. and Shorthouse A.A.: Properties of cytotoxic peptide-formed ion channels. Am. J. Physiol. Cell Physiol. 278: C1063-C1087 (2000)

18.  Ogris M., et al.: Melittin enables efficient vesicular escape and enhanced nuclear access of non-viral gene delivery vectors. J. Biol. Chem. 276: 47550-47555 (2001)

19.  Kichler A., et al.: Polyethylenimine-mediated gene delivery: a mechanistic study. J. Gene Med. 3: 135-144 (2001)

20.  Lafreniere R. and Rosenberg S.A.: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res. 45: 3735-3741 (1985)

21.  Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., Gilboa E.: Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res. 50: 7820-7825 (1990)

22.  Creasey A., Reynolds M., Laird W.: Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res. 46: 5687-5690 (1986)

23.  Ferrone S., Marincola F.M.: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16: 487-494 (1995)

24.  Garrido F., Ruiz-Cabello F., Cabrera T., et al.: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 18: 89-96 (1997)

25.  Coulie G.P., Hanagiri T., Takenoyama M.: From tumor antigens to immunotherapy. Int. J. Clin. Oncol. 6: 163-170 (2001)

26.  Morel S., Lévy F., Burlet-Schiltz O., et al.: Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dedritic cells. Immunity 12: 107-117 (2000)

27.  Freeman S.M., Ramesh R., Munshi A., Whartenby K.A., Freeman J.L., Marrogi A.J.: In situ use of suicide genes for cancer therapy. In: Gene therapy of cancer, Eds. Lattime, E.C. and Gerson, S.L. Academic Press, San Diego, CA, pp. 55-176 (1999)

28.  Yasawa K, Fisher W., Brunicardi C.: Current Progress in Suicide Gene Therapy for Cancer. World J. Surg. 26: 783-789 (2002)

29.  Farzaneh F., Treize r U., Sterry W., Walden P.: Gene therapy of cancer. Immun. Today 19: 294-6 (1998)

30.  Chen S.H., Shine H.D., Goodman J.C., Grossman R.G., Woo S.L.C.: Gene therapy for brain tumors: regression of experimental glioma by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91: 3054-3057 (1994)

31.  Caldas C., Hahn S.A., da Costa L.T., et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-31 (1994)

32.  Gustin A., Pederson L., Miller R., Chan C., Vickers S.: Applications of Molecular Biology Studies to Gene Therapy Treatment Strategies. World J. Surg. 26: 854-860 (2002)

33.  Vousden K.H.: p53: death star. Cell 103: 691-694 (2000)

34.  Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C.: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878 (1994)

35.  Zeimet A.G., Riha K., Berger J., Widschwendter M., Hermann M., Daxenbichler G., Marth C.: New insights into p53 regulation and gene therapy for cancer. Biochem. Pharmacol. 60: 1153-1163 (2000)

36.  Eastham J.A., Grafton W., Martin C.M., Williams B.J.: Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol. 164: 814-819 (2000)

37.  Grana X., Reddy E.: Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes, and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219 (1995)

38.  Kamb A., Gruis N., Weaver-Feldhaus J., et al.: A cell cycle regulator potentially involved in genes of many tumor types. Science 264: 436-440 (1994)

39.  Merlar A., Herman J., Mao L., et al.: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDK2/MTS1 in human cancers. Nat. Med. 1: 686-692 (1995)

40.  Nobori T., Miura K., Wu D., Lois A., Takabayashi K., Carson D.: Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753- 756 (1994)

41.  Wigler M.H., Parsons R.A., Druck T., et al.: Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res. 55: 5348-53 (1995)

42.  Kastury K., Baffa R., Druck T., et al.: Potential gastro-intestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56: 978-83 (1996)

43.  Naylor S.L., Johnoson B.E., Minna J.D., et al.: Loss of heterozygosity of chromosome 3p markers in smafl cell lung cancer. Nature 329: 451-54 (1987)

44.  Hibi K., Takahashi T., Yamakawa K., et al.: Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 7: 445-49 (1992)

45.  Huebner K., Hadaczek P., Siprashvili Z., et al.: The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochem. Biophys. Acta. (Reviews on Cancer) 1332: M65-M70 (1997)

46.  Glover T.W., Coyle-Morris J.F., Frederick P.L, et al.: Translocation t(3;8) (p14.2;q24,1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lymphocytes. Cancer Genet. Cytogenet. 31: 69- 73(1988)

47.  Pekarsky Y., Zanesi N., Palamarchuk A., Hueber K., Croce C.: FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol. 3: 748-754 (2002)

48.  Jahnsen B. and Zangemeister-Wittke U.: Antisense therapy for cancer – the time of the truth. Lancet Oncol. 3: 672-683 (2002)

49.  Hahn S.A., Schutte M., Hoque A.T.M.S., et al.: DPC4, a candidate tumor suppressor gene at 18q21.1. Science 271: 350-353 (1996)

50.  Moskaluk C.A., Kern S.E.: Molecular genetics of pancreatic carcinoma. In Reber HA, editors, Pancreatic Cancer: Pathogenesis, Diagnosis and treatment, Humana Press, Totowa, NJ (1998)

51.  Beerli R.R., Barbas C.F. III: Engineering polydactyl zinc-finger transcription factors. Nature Biotechnology 20: 135-141 (2002)

52.  Pabo C.O., Peisach E., Grant R.A.: Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70.

53.  Pasqualini R., Barbas III C., Arap W.: Vessel maneuvers: zinc fingers promote angiogenesis. Nature Med. 8: 1427-1432 (2002)

54.  Beeli R.R., Dreier B., Barbas III C.F.: Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 971: 495- 1500 (2000)

55.  Folkman J.: Tumor angiogenesis: Therapeutic implications. N. Eng. J. Med. 333: 1757-1763 (1971)

56.  Folkman J.: The vasculization of tumors. Sci. Am. 234: 58-73 (1976)

57.  Chen Q.R., Zhang L., Gasper W., Mixson J.: Targeting tumor angiogenesis with gene therapy. Mol. Gen. Metab. 74: 120-127 (2001)

58.  Folkman J.: Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95: 9064-9066 (1998)

59.  Tanaka T., Manome Y., Wen P., Kufe D.W., Fine H.A.: Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med. 3: 437-442 (1997)

60.  Boggio K., Di Carlo E., Rovero S., Cavallo F., Quaglino E., Lollini P.L, Nanni P., Nicoletti G., Wolf S., Musiani P., Forni G.: Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60: 359-364 (2000)

61.  Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., Maione T.E.: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J. Natl. Cancer Inst. 82: 848-853 (1990)

62.  O’Reilly M.S., Holmgren L., Chen C., Folkman J.: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 2: 689-692 (1996)

63.  O’Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J.: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285 (1997)

64.  Saito R., Mizuno M., Kumabe T., Yoshimoto T., Tanuma S., Yoshida J.: Apoptotic DNA endonuclease (DNAase-gamma) gene transfer induces cell death accompanying DNA fragmentation in human glioma calls. J. Neurooncol. 63: 25-31 (2003)

65.  Spalletti-Cernia D., Sorrentino R., Di Gaetano S., Arciello A., Garbi C., Piccoli R., D’Allessio G., Vecchio G., Laccetti P., Santoro M.: Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase mediated induction of apoptosis. J. Clin. Endocrinol. Metab. 88: 2900-7 (2003)

66.  Shenk T.: Adenoviridae: The Viruses and Their Replication. In: Fields virology, 3^rd ed, Eds. Knipe D.M., Fields B.N., Howley P.M. Lippincott-Raven, Philadelphia, Pa, pp 2111-2148 (1996)

67.  Kirn D.: Selectively replicating viruses as therapeutic agents against cancer. In: Gene therapy of cancer, Eds. Lattime E. C. and Gerson S.L. Academic Press, San Diego, CA, pp 235-248 (1999)

68.  Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376 (1996)

69.  Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639-645 (1997)

70.  Rafferty J.A., Hickson I., Chinnasamy N., Lashford L.S., Margison G.P., Dexter T.M., Fairbairn L.J.: Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metastas. Rev. 15: 365-383 (1996)

71.  Gunji Y., Ochiai T., Shimada H., Matsubara H.: Gene Therapy for Cancer. Surg. Today 30: 967-973 (2000)

72.  Rots M.G., Curiel D.T., Gerritsen W.R., Haisma H.T.: Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. Journal of Controlled Release 87: 159-165 (2003)

73.  Haisma H.J., Pinedo H.M., Rijswijk A., der Meulen-Muileman L., Sosnowski B.A., Ying W., Beusechem V.W., Tillman B.W., Gerritsen W.R., Curiel D.T.: Tumor-specific transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 6: 1469-1474 (1999)

74.  Heideman D.A., Snijders P.J., Craanen M.E., Bioemena E., Meijer C.J., Meuwissen S.G., van Beusechem V.W., Pinedo H.M., Curiel D.T., Haisma H.J., Gerritsen W.R.: Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther. 8: 342-351 (2001)

75.  Haviv Y.S., Curiel D.T.: Conditional gene targeting for cancer gene therapy. Adv. Drug Deliv. Rev. 53: 135-154 (2001)

76.  Pitts J.D.: Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol. Carcinog. 11: 127- ISO (1994)

77.  Wadia J.S. and Dowdy S.F.: Protein transduction technology. Curr. Opin. Biotechnol. 13: 52-56 (2002)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr